DEFINITION AND STANDARDIZATION OF INTERSTITIAL LUNG DISEASE ASSESSMENT BY ULTRASOUND: RESULTS FROM A DELPHI PROCESS AND WEB-RELIABILITY EXERCISE BY THE OMERACT ULTRASOUND WORKING GROUP (WG)

Andrea Delle Sedie1, Lene Terslev2, George Bruyn3, Tomás Cazenave4, Stavros Chrysidis5, Mario Diaz6, Marco Di Carlo7, Marilena Frigato8, Luna Gargani9, Marwin Gutierrez10, Alózinha Hovecar11, Annamaria Iagnocco12, Aaron Juche13, Peter Mandl14, Esperanza Naredo15, Mohammed A. Mortada16, Carlos Pineda17, Francesca Porta18, Viviana Ravagnani8, Carlo Alberto Scirè18, Teodora Serban19, Kate Smith20, Maria Stoienoiu21, Marika Tardella22, Richard Wakefield22, Maria-Antonietta D’Agostino23, OMERACT US Task Force on Lung US in Rheumatology, 1University of Pisa, Pisa, Italy; 2Rigshospitalet-Glostrup, Copenhagen, Denmark; 3Leeds, Lelstad, Netherlands; 4Instituto de Rehabilitacion Psicosocial, Buenos Aires, Argentina; 5Estbjerg, Esbjerg, Denmark; 6Fundacíon Santa Fe, Bogotá, Colombia; 7Università Politecnica delle Marche, Jesi, Italy; 8A.S.T.Mantaova, Mantova, Italy; 9National Research Council, Pisa, Italy; 10Instituto Nacional de Rehabilitación, Mexico City, Mexico; 11UMC, Ljubljana, Slovenia; 12Università degli Studi di Torino, Torino, Italy; 13Immanuel-Krankenhaus, Berlin, Germany; 14Medical University of Vienna, Vienna, Austria; 15Fundación Jiménez Díaz, Madrid, Spain; 16Zagazig University, Zagazig, Egypt; 17Pistoia, Pistoia, Italy; 18University of Ferrara, Ferrara, Italy; 19Ospedale La Colletta – ASL3, Genoa, Italy; 20NHIR Leeds Biomedical Research Centre, Leeds, United Kingdom; 21Université catholique de Louvain, Bruxelles, Belgium; 22Loma Linda University, Loma Linda, United States of America; 23Université Paris Ouest-Versailles-Saint Quentin en Yvelines, Paris, France

Background: Interstitial lung disease (ILD) evaluation is challenging, given the low sensitivity of X-ray and pulmonary function tests, and limited accessibility and radiation linked to repetitive HRCT. Lung Ultrasound (US) has shown potential in the evaluation of ILD of autoimmune diseases including systemic sclerosis.

Objectives: To define and assess the reliability of definitions of US-detected findings in ILD.

Methods: A taskforce (TF) within the OMERACT US WG performed a literature review (LR) to identify US lesions in ILD, a Delphi exercise to define these lesions and a web-based exercise to test the reliability of these definitions by using either intrinsic correlation coefficient (ICC) or kappa statistics. Prior to the Delphi exercise all participants received training files and were subsequently asked to provide clips on BL, PLI and normal findings. Based on the results of the LR, which identified B-lines with an increase in thickness, focal, diffuse, or nodular pattern, the TF members in order to score them (semiquantitatively, 0-2) and for PLI and total number for BL.

Results: The 3 Delphi rounds and the web-based exercise were computed to the TF members in order to score them (semiquantitatively, 0-2) of 80 high-quality clips (30 for PLI, 50 for BL), was selected and distributed to the TF members in order to score them (semi-quantitatively, 0-2 for PLI and total number for BL).

Conclusion: We aim in our study to evaluate the predictive role of ILC2 and ILC3 in SSC patients.

Disclosure of Interests: Andrea Delle Sedie Speakers bureau: Abbvie, UCB, Celgene, MSD, Lene Terslev Speakers bureau: Speakers fee from : Roche, Novartis, Pfizer, MSD, BMS, Celgene, George Bruyn : None declared, Tomás Cazenave: None declared, stavros chrysidis: None declared, Mario Diaz: None declared, Marco Di Carlo: None declared, Marilena Frigato: None declared, Luna Gargani: None declared, Marwin Gutierrez: None declared, AlOZJUA HOCEVART: None declared, Annamaria Iagnocco: None declared, Aaron Juche: None declared, Peter Mandl: None declared, Esperanza Naredo Naredo Consultant for: Abbvie, Speakers bureau: Abbvie, Speakers bureau: Abbvie, Roche, Bristol-Myers Squibb, Pfizer, UCB, Lilly, Novartis, Janssen, and Celgene GmbH, Mohammed A Mortada: None declared, Carlos Pineda: None declared, Francesca Porta: None declared, Viviana Ravagnani: None declared, Carlo Alberto Scirè: None declared, Teodora Serban: None declared, Kate Smith: None declared, Maria Stoienoiu: None declared, Marika Tardella: None declared, Karina Torralba: None declared, Richard Wakefield: None declared, Maria-Antonietta D’Agostino: None declared


PREDICTIVE VALUE OF INNATE LYMPHOID CELLS IN SYSTEMIC SCLEROSIS

Alina Soare, Stefanie Weber, Markus Luber, Simon Raubner, Thomas Wohlfahrt, Georg Schett, Jörg Distler, Andreas Ramming, Friedrich-Alexander-University (FAU) Erlangen-Nürnberg and Universitätsspital Klinikum Erlangen, Department of Internal Medicine 3 – Rheumatology and Immunology, Erlangen, Germany

Background: Systemic sclerosis (SSc) is a chronic autoimmune disease with a high morbidity and mortality. Activation of the immune system is a characteristic feature of SSc. Numerous studies have suggested that type 2 and type 3 cytokines are key drivers of progressive fibrosis. Recently, innate lymphoid cells (ILC) are emerging as an important cellular source of type 2 and type 3 cytokines triggering fibrotic tissue remodeling independently of the adaptive immune system. ILCs are characterized by the absence of conventional lineage markers. Similar to T cells, they are categorized into three groups (ILC1, ILC2, ILC3), according to distinct patterns of cytokine production and the requirement of specific transcription factors guiding their development and function. Increased levels of ILC2 were found in patients with SSc. However, the contributive role of ILC2 and ILC3 in pathogenesis of SSc is not completely understood.

Objectives: We aim in our study to evaluate the predictive role of ILC2 and ILC3 in SSC patients.

Methods: We conducted an observational retrospective study on 52 patients with SSc fulfilling the 2013 ACR/EULAR classification criteria. Yearly clinical, laboratory and investigational data according to EUSTAR recommendations were collected. Blood samples collected between 15.09.2014 and 15.01.2015 were analyzed by flow cytometry and ILC2 and ILC3 counts were measured. The predictive value of ILC2 and ILC3 during a 2-year follow-up was analyzed using SPSS 21.0. ILC3 counts were also analyzed in skin sections (10 patients with SSc and 10 healthy controls) by immunofluorescence (IF) staining using two complementary panels of markers. Cytokine production of skin resident ILC3s was additionally analyzed by IF staining.

Results: S2 patients were included in the study, 78% female, 63% limited cutaneous SSc with a mean follow-up time of 2.85 ± 1.28 years. At baseline we have shown that circulating ILC2s are significantly increased compared to gender and age-matched healthy controls. Increased numbers of ILC2s significantly correlated with worsening of mRSS calculated by five point increase in mRSS or 25% increase from baseline (p < 0.0001; 95% CI 1.27 – 3.49). Worsening of forced vital capacity (FVC) was assessed as 5% decrease over 2 years was also significantly correlated with an increased number of ILC2s (p < 0.0001; 95% CI 1.27 – 3.49). In contrast, we did not find any correlation regarding increase in pulmonary arterial pressure assessed by echocardiography. Although new appearance of digital ulcers could not be predicted by ILC2 counts, increased numbers of ILC2s were correlated with digital ulcers at follow-up. ILC2s did not have a predictive value for death during the follow-up time. In contrast to ILC2, circulating ILC3s were not found to be correlated with worsening of disease activity. However, ILC3s were prominent in fibrotic skin of SSc patients compared to healthy controls, and showed strong production of IL-17.

Conclusion: Here, we provide first evidence for a role of ILC2s as potential prognostic marker of disease progression in SSc. Circulating ILC3 counts were not elevated in SSc. However, ILC3s showed strong cytokine production in the fibrotic skin of SSc patients. The functional impact has to be further evaluated.

Disclosure of Interests: Alina Soare: None declared, Stefanie Weber: None declared, Markus Luber: None declared, Simon Raubner: None declared, Thomas Wohlfahrt: None declared, Georg Schett: None declared, Jörg Distler: None declared, Andreas Ramming Grant/research support from: Abbvie, Disclosure of Interests: Andrea Delle Sedie Speakers bureau: Abbvie, UCB, Celgene, MSD, Lene Terslev Speakers bureau: Speakers fee from : Roche, Novartis, Pfizer, MSD, BMS, Celgene, George Bruyn: None declared, Tomás Cazenave: None declared, stavros chrysidis: None declared, Mario Diaz: None declared, Marco Di Carlo: None declared, Marilena Frigato: None declared, Luna Gargani: None declared, Marwin Gutierrez: None declared, AlOZJUA HOCEVART: None declared, Annamaria Iagnocco: None declared, Aaron Juche: None declared, Peter Mandl: None declared, Esperanza Naredo Naredo Consultant for: Abbvie, Speakers bureau: Abbvie, Speakers bureau: Abbvie, Roche, Bristol-Myers Squibb, Pfizer, UCB, Lilly, Novartis, Janssen, and Celgene GmbH, Mohammed A Mortada: None declared, Carlos Pineda: None declared, Francesca Porta: None declared, Viviana Ravagnani: None declared, Carlo Alberto Scirè: None declared, Teodora Serban: None declared, Kate Smith: None declared, Maria Stoienoiu: None declared, Marika Tardella: None declared, Karina Torralba: None declared, Richard Wakefield: None declared, Maria-Antonietta D’Agostino: None declared